started · updated
Respiratory research advances asthma and COPD treatments
Recent medical research and clinical studies are advancing the understanding and treatment of chronic respiratory diseases, including asthma and COPD.
Studies have identified that approximately 10% of asthma patients suffer from a steroid-resistant form of the disease. Researchers have discovered that the simultaneous presence of Aspergillus mold and certain bacterial molecules in the airways can trigger a significantly more aggressive immune response than either element alone, potentially explaining why standard treatments fail for some.
In the field of COPD management, the CHOROS ORION study, presented at the European Respiratory Society Congress, demonstrated that a triple inhalation therapy delivered via a single inhaler (budesonide/glycopyrronium/formoterol) led to a reduction in healthcare resource utilization over a 52-week period compared to the preceding year.
Clinical advancements are also focusing on improving diagnostic tools for bronchiectasis and seeking new pathways for remission in severe asthma cases to improve patient quality of life.
Entities
Aspergillus · European Respiratory Society · Micaela Romagnoli · Ospedale Ca' Foncello
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Approximately 10% of asthma patients suffer from a steroid-resistant form of the disease. healthy.thewom.it
- [○ 1 SOURCE] Exposure to Aspergillus mold and bacterial molecules together triggers a more aggressive immune response than either alone. healthy.thewom.it
- [○ 1 SOURCE] The CHOROS ORION study showed that triple inhalation therapy in a single inhaler reduced healthcare resource use in COPD patients over 52 weeks.